Feast and famine approach to dieting effective for weight loss
Fasting on alternate days may help shave off the pounds better than other intermittent fasting and calorie restriction diets, according to a new study.
While scientists have called for more work to confirm the findings, a new review suggests the so-called feast and famine approach to dieting may have greater benefits when it comes to weight loss.
Alternate day fasting involves a 24-hour fast on every second day, and has become more popular in recent years.
Other intermittent fasting approaches to dieting have also grown in popularity, including time-restricted eating, where people only eat for a certain number of hours in the day, such at the 16:8 diet involving a 16-hour fasting period followed by an eight-hour eating; and whole-day fasting, which includes the 5:2 diet involving five days of eating and two days of fasting periods.
Researchers from Scotland, the US, Canada and Germany wanted to compare fasting methods to continuous energy restriction diets by looking at all of the available evidence.
They examined data from 99 studies involving more than 6,500 people.
People involved in the studies had an average body mass index (BMI) of 31 and almost nine in 10 (89%) had pre-existing health conditions.
The research team found that both intermittent fasting diets and calorie restricted diets led to weight loss.
But compared with continuous energy restriction, alternate day fasting was the only strategy to show benefit in body weight reduction, with people on this diet losing 1.29kg more, according to the study, which has been published in The BMJ.
The authors said that alternate day fasting showed a 'trivial' reduction in body weight compared with both time restricted eating and whole day fasting
'Minor differences were noted between some intermittent fasting diets and continuous energy restriction, with some benefit for an alternate day fasting strategy with weight loss in shorter duration trials,' the authors wrote.
'All intermittent fasting strategies and continuous energy restriction diets showed a reduction in body weight when compared with an ad-libitum diet
'Of three intermittent fasting diets (ie, alternate day fasting, time restricted eating, and whole day fasting), alternate day fasting showed benefit in body weight reduction compared with continuous energy restriction.'
Around 29% of adults in the UK are obese.
Last week the NHS' top doctor said that weight loss jabs could be as transformative as statins.
Later this month GPs in England will be allowed to prescribe mounjaro, also known as tirzepatide, for the first time.
Patients previously needed to access the drugs through a special weight loss service.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
19 minutes ago
- Bloomberg
Chinese Biotech Showcases Challenger to Eli Lilly's Obesity Drug
An obesity drug from China helped patients lose a lot of weight in a late-stage clinical trial, making it a prospective new challenger to blockbusters from Novo Nordisk A/S and Eli Lilly & Co. Hangzhou Sciwind Biosciences Co. said its drug, ecnoglutide, led to more than 15% weight loss after 48 weeks when given at the highest dose. Although the trial did not compare ecnoglutide directly with existing medicines, the results were very similar to what Lilly's Zepbound showed in previous China studies, Sciwind Chief Executive Officer Hai Pan said in an interview.
Yahoo
24 minutes ago
- Yahoo
'A beautiful partnership': Children take part in 'Summer at Sem, Explorations with the Y' program
Jun. 21—Which solution was the best for making lots of big bubbles? Turning to the 6- to 9-year-olds in her classroom, Wyoming Seminary science teacher asked them to remember their previous experiments. Did the store-bought solution work best? "No!" What about the homemade solution with sugar? "No!" Could it have been the homemade solution with glycerin? "Yes!" came the answer from a dozen budding scientists, who eagerly blew huge streams of bubble using their best solution and bubble blowers that had been handcrafted from plastic bottles with the bottoms cut off and replaced by a cloth that was held in place by a rubber band. The kids vied to make the tallest towers of bubbles, and some of them used their hands to sculpt bubbles into interesting shapes. It was all part of the fun at Summer at Sem, Explorations with the Y, a 3-week program that attracted 113 campers to Wyoming Seminary's Lower School campus in Forty Fort for sessions as diverse as LEGO robotics, photography, basketball and waterplay. "We have everything here," Cheryl Connolly, Wyoming Seminary director of advancement, said Friday, as children took part in the final day of camping activities. "It's a beautiful partnership," Sara Hargadon Michaels, camp director, said of this year's cooperative effort between Wyoming Seminary and the Y, which welcomed students from other schools to join Wyoming Seminary's program, which dates back to the 1990s. Michaels said she had seen children blossom at the camp. "You see the timidness of their first arrival turn into vibrancy and confidence as they soak up the energy of the camp." In one classroom, children sang about waddling ducks approaching a lemonade stand as they rehearsed a skit. In another, Wilkes-Barre Area kindergarten teacher Maria Hayward helped them use up some of their physical energy playing with balloons before they headed outdoors to draw with chalk. And in a gym, dozens of campers were dribbling basketballs. With faculty members from Wyoming Seminary and program specialists from the YMCA facilitating, Michaels said, "what has been provided has only enhanced what has traditionally been presented in the past. Favorites such as LEGO Stop Motion, Chemistry, Magic School Bus, Ocean Explorations, Cardboard Creations and Chef for a Day were joined by Pickleball, Speed and Agility and Sports from Around the World." While those camps were targeted at first through eighth graders, toddlers stayed busy with waterworks, sensory play and more with their teacher Margaret McCann in Arlington House, a separate building on the campus. "The partnership has been a fantastic experience, one that we hope to build on moving forward," Michaels said.
Yahoo
30 minutes ago
- Yahoo
GE HealthCare drives innovation in theranostics with latest technological advances
GE HealthCare is helping advance clinical and operational excellence in theranostics and molecular imaging through a comprehensive portfolio of AI-powered imaging technologies, radiopharmaceuticals, cyclotrons, chemistry systems, and workflow-optimizing software—designed to support personalized, data-driven care across the entire patient journey. At #SNMMI25, the company is proud to introduce LesionID™ Pro with automated zero-click pre-processing,i which aims to help physicians minimize manual segmentation required to access patient-specific insights that can play a key role in delivering precision care with confidence. CHICAGO, June 21, 2025--(BUSINESS WIRE)--At this year's Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, GE HealthCare is spotlighting the future of precision care with its innovative portfolio of theranostics-enabling solutions designed to help drive clinical and operational excellence. Making its debut, GE HealthCare's MIM Software introduces LesionID Pro with automated zero-click pre-processingi – an AI-powered innovation to help aid physician decision making and therapy response monitoring. With cancer accounting for over 10 million deaths globally each year,ii the rise of precision care – particularly theranostics – is offering new hope to patients. By combining advanced diagnostic imaging and radiopharmaceuticals with targeted therapies, theranostics enables a personalized, patient-centric approach that may help improve disease detection, treatment accuracy, and overall quality of life. "Precision care is the future of oncology—and theranostics is at the heart of that future. The integration of advanced imaging and AI-powered software is accelerating the adoption of theranostics in clinical practice," shares Shyam Srinivas, MD, PhD, Chief of Nuclear Medicine, Associate Clinical Professor, Department of Radiological Sciences, University of California, Irvine. "With tools like GE HealthCare's Omni Legend, StarGuide, and MIM software at our disposal, we now have the ability to visualize disease with great clarity, quantify tumor burden efficiently, and make fast, informed decisions. These advancements are not only helping enhance diagnostic accuracy and therapy monitoring but are also opening the door to dosimetry—ultimately helping improve outcomes for our patients. This is precision care in action, and it's making a real difference in patients' lives." Central to the practice of theranostics is molecular imaging, such as positron emission tomography (PET) and single photon emission computed tomography (SPECT), which provides detailed, patient-specific insights to guide and monitor treatment. However, accessing these insights – like whole-body tumor burden, which represents the total amount of cancer is in the body – has traditionally required time-consuming manual analysis, resulting in clinical and operational challenges. In response, GE HealthCare's MIM Software is introducing LesionID Pro with automated zero-click pre-processing,i designed with AI-powered automation to help physicians access reliable whole-body tumor burden statistics without having to spend hours manually segmenting lesions, removing normal physiologic uptake, and registering multiple patient images for comparison. In addition to turning manual pre-processing into a zero-click experience, this new version of LesionID Pro comes with significant algorithm improvements that provide physicians with a precise whole-body tumor volume to review and finalize. Intuitive, user-friendly tools were intentionally designed with input from leading theranostics practitioners with the ultimate goal of making whole-body tumor burden analysis a practical clinical reality and help shorten physicians' time-to-report. "At GE HealthCare, we are dedicated to providing clinicians the precision care tools needed for the adoption and practice of theranostics," shares Jean-Luc Procaccini, President & CEO, Molecular Imaging & Computed Tomography, GE HealthCare. "We designed our portfolio of precision care solutions to evolve with healthcare system needs and help support a patient's entire care journey – from the imaging equipment needed for a noninvasive look at a patient's anatomy and treatment monitoring, to novel radiopharmaceuticals used to diagnose and monitor disease and the systems required to produce them, to the software optimized to enable data-driven decision-making. In the hands of clinicians, these tools help advance the global practice of personalized medicine and help improve patient outcomes." Also on display at #SNMMI25, as part of GE HealthCare's comprehensive portfolio of theranostics-enabling solutions for clinical and operational excellence, are the following innovations: MINItrace Magni,iii GE HealthCare's newest cyclotron technology, designed with a small footprint (about the size of a commercial refrigerator) and the goal of providing an easy-to-site, easy-to-install solution for the reliable, in-house production of commercial PET tracers and radiometals, including Gallium-68, used in diagnostic imaging to support personalized care plans. Adoption of such easy-to-site, easy-to-install technology may help enhance the capabilities of the healthcare system but also grant clinicians the ability to offer a variety of tracers to their patients and encourage the practice of precision care locally, helping fuel inhouse Theranostics capabilities. Omni Legend is a performance-focused PET/CT designed to evolve and help meet growing healthcare system demands by enabling clinicians to reduce dose by up to 40%iv while maintaining exceptional image quality. Supportive of the diagnostic portion of theranostics, the system continues to gain in popularity, representing the company's fastest-ever-selling PET/CT.v StarGuide is a digital SPECT/CT with a 12 CZT detector design that delivers high-quality 3D images and short scan times. Optimized for certain theranostic procedures, the system is designed to help clinicians pinpoint the size, shape, and position of lesions and monitor therapy with exceptional precision. Its flexibility in patient scanning and workflow efficiencies also support high patient throughput and help reduce complexity. For oncology patients, especially those in pain, short scans can help enhance comfort and overall experience. Aurora is an advanced dual-head SPECT/CT designed with excellent diagnostic capabilitiesvi and streamline workflows, offering clinicians excellent image quality and operational efficiency. Its CT has a 40 mm detector – twice the detector coverage compared to CTs of other hybrid systemsvii – with the ability to reduce the dose up to 82%,viii support accurate quantitation, and help clinicians make the personalized care decisions that are at the heart of theranostics. Theranostics Pathway Manager Tile is an easy-to-use application, available on GE HealthCare's Command Center software, that is designed to simplify the time-consuming task of coordinating the theranostics care pathway. It does so by tracking patient readiness for therapy, eliminating the need for manual data gathering across disparate systems (e.g., labs, scheduling, ordering, spreadsheets), and providing a unified, up-to-date view of each patient's treatment journey. Oregon Health & Science University will be an early adopter. "Every day counts when it comes to cancer care. The latest theranostics solutions will help our care teams more quickly and easily keep tabs on patient readiness and reduce patient coordination time—freeing up more time for clinicians to focus on direct patient care," says Erik Mittra, M.D., Ph.D., professor of diagnostic radiology in the at Oregon Health & Science University. Altogether, GE HealthCare has the unique ability to provide solutions along every step of the theranostics care pathway. Our integrated portfolio of solutions provides clinicians with the isotopes, imaging, informatics, and molecular imaging agents necessary for the practice and advancement of precision care. For more information on GE HealthCare's innovative portfolio of theranostics-enabling solutions, please visit SNMMI show attendees are also encouraged stop by the company's booth (#638 and #1023) at New Orleans Ernest N. Morial Convention Center in New Orleans, Louisiana from June 21-24. About GE HealthCare Technologies Inc. GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. We aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected and compassionate care, while simplifying the patient's journey across care pathways. Together, our Imaging, Advanced Visualization Solutions, Patient Care Solutions and Pharmaceutical Diagnostics businesses help improve patient care from screening and diagnosis to therapy and monitoring. We are a $19.7 billion business with approximately 53,000 colleagues working to create a world where healthcare has no limits. GE HealthCare is proud to be among 2025 Fortune World's Most Admired Companies™. Follow us on LinkedIn, X, Facebook, Instagram, and Insights for the latest news, or visit our website for more information. i LesionID Pro with automated zero-click pre-processing is 510(k)-pending with the U.S. FDA. Not CE Marked and not licensed in accordance with Canadian law. Not available for sale in the United States, Europe, Canada, or any other Cancer. World Health Organization. Published February 3, 2022. Accessed March 2, Technology in development that represents ongoing research and development efforts. These technologies are not products and may never become products. Not CE Omni Legend 21cm as compared to Discovery MI Gen1 20cm. As demonstrated in phantom testing.v Based on orders data of GE HealthCare PET/CT systems since Compared to NM/CT 870 As compared to NM/CT 870 DR with Optima 540 a ASiR-V reduces dose by 50% to 82% relative to FBP at the same image quality (Image quality as defined by low contrast detectability).viii b In clinical practice, the use of ASiR‐V may reduce CT patient dose depending on the clinical task, patient size, anatomical location, and clinical practice. A consultation with a radiologist and a physicist should be made to determine the appropriate dose to obtain diagnostic image quality for the particular clinical task. Low Contrast Detectability (LCD), Image Noise, Spatial Resolution and Artifact were assessed using reference factory protocols comparing ASiR‐V and FBP. The LCD was measured using 0.625 mm slices and tested for both head and body modes using the MITA CT IQ Phantom (CCT183, The Phantom Laboratory), using a model observer method. View source version on Contacts GE HealthCare Media Contact: Margaret SteinhafelM +1 608 381 Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
